Core Viewpoint - 89bio, Inc. has entered into a merger agreement with Roche, with stockholders set to receive up to $20.50 per share, including a cash payment of $14.50 at closing and a contingent value right (CVR) of up to $6.00 per share, representing a total equity value of approximately $3.5 billion [1][3][6] Company Overview - 89bio is a clinical-stage biopharmaceutical company focused on developing therapies for liver and cardiometabolic diseases, currently in Phase 3 trials for its lead candidate, pegozafermin, targeting metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [9] Transaction Details - The merger agreement includes a tender offer for all outstanding shares at $14.50 per share, totaling an aggregate payment of $2.4 billion, with additional contingent payments based on specific milestones [3][4] - The CVR includes potential cash payments of $2.00 per share upon the first commercial sale of pegozafermin, $1.50 per share upon achieving annual net sales of at least $3.0 billion, and $2.50 per share for annual net sales of at least $4.0 billion [5] Strategic Implications - The merger aims to leverage Roche's global development and commercialization capabilities to enhance the potential benefits of pegozafermin for patients and unlock significant shareholder value [2] - Roche plans to integrate pegozafermin into its cardiovascular, renal, and metabolism portfolio, aiming to transform the standard of care for patients with moderate to severe MASH [2]

Core Viewpoint - 89bio, Inc. has entered into a merger agreement with Roche, with a cash acquisition price of $14.50 per share, representing a premium of approximately 79% over its closing stock price on September 17, 2025, and a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis [1][3][5] Company Overview - 89bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases, currently in Phase 3 trials for its lead candidate, pegozafermin [10] - Pegozafermin is a fibroblast growth factor 21 (FGF21) analog designed to treat metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG) [10] Transaction Details - Roche will commence a tender offer to acquire all outstanding shares of 89bio for $14.50 per share, with an aggregate payment of $2.4 billion, plus a non-tradeable contingent value right (CVR) for up to an additional $6.00 per share [3][5] - The total transaction equity value could reach approximately $3.5 billion on a fully diluted basis, contingent upon the achievement of specified milestones [1][3][5] Contingent Value Rights (CVR) - The CVR will provide cash payments based on the achievement of certain milestones, including: - $2.00 per share upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients by March 31, 2030 - $1.50 per share if annual net sales reach at least $3.0 billion by December 31, 2033 - $2.50 per share if annual net sales reach at least $4.0 billion by December 31, 2035 [6] Strategic Implications - The merger aims to combine 89bio's innovative therapy with Roche's global development and commercialization capabilities, enhancing the potential benefits for patients and unlocking significant shareholder value [2] - Roche plans to integrate pegozafermin into its cardiovascular, renal, and metabolism portfolio, aiming to transform the standard of care for patients with moderate to severe MASH [2]

Core Insights - TGS has announced the PAMA Phase II 3D multi-client survey in the Equatorial Margin area offshore Brazil, expanding its coverage significantly in a highly prospective basin [1][2][4] - The survey will cover an additional 11,500 square kilometers, including blocks nominated for upcoming license rounds in 2026 and 2027 [2] - The project is supported by industry funding and utilizes advanced TGS GeoStreamer technology for high-quality data acquisition [2][4] Industry Context - The Pará-Maranhao Basin is recognized for its functioning deepwater petroleum system, attracting interest due to discoveries in neighboring countries like Guyana and Suriname [3] - TGS aims to leverage its advanced acquisition capabilities to provide substantial value for clients' exploration activities in the basin [4] - The ongoing Megabar extension multi-client project in the Barreirinhas Basin will see two Ramform Titan-class vessels active in the Equatorial Margin through the remainder of 2025 [4]

Core Viewpoint - Roche has entered into a definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical company focused on innovative therapies for liver and cardiometabolic diseases, with the transaction expected to close in Q4 2025 [1][9]. Group 1: Acquisition Details - Roche will commence a tender offer to acquire all outstanding shares of 89bio at a price of US$14.50 per share in cash, plus a non-tradeable contingent value right (CVR) for milestone payments of up to US$6.00 per share, representing a total equity value of approximately US$2.4 billion and a total deal value of up to US$3.5 billion [5][7]. - The acquisition price represents a premium of approximately 52% to 89bio's 60-day volume-weighted average price (VWAP) as of September 17, 2025 [5][7]. - The merger agreement has been unanimously approved by the boards of both Roche and 89bio [5]. Group 2: Strategic Rationale - The acquisition supports Roche's strategy to enhance its portfolio in cardiovascular, renal, and metabolic diseases (CVRM), particularly targeting conditions associated with obesity and metabolic dysfunction [2][3]. - Pegozafermin, 89bio's lead candidate, is positioned to potentially offer best-in-disease efficacy for moderate to severe Metabolic Dysfunction-Associated Steatohepatitis (MASH) patients, addressing critical unmet needs in this area [3][7]. - The distinct mechanism of action of pegozafermin may create synergies with Roche's existing CVRM portfolio, allowing for future combination development [2][3]. Group 3: Market Context - MASH is a serious and increasingly prevalent form of fatty liver disease, affecting an estimated 5-7% of the global adult population, with a significant association with obesity and type 2 diabetes [11]. - The condition can progress to severe complications, including cirrhosis and hepatocellular carcinoma, highlighting the need for effective treatment options [11]. Group 4: Employee Integration - Current employees of 89bio will join Roche's Pharmaceuticals Division as part of the acquisition [4].

Core Viewpoint - The article highlights the significant impact of artificial intelligence (AI) on Wall Street, emphasizing the increased spending on data centers as a key area for investment opportunities [1] Group 1: Industry Insights - The surge in AI adoption is driving substantial investments in data centers, indicating a shift in focus for financial institutions [1] - Companies involved in data center infrastructure and services are poised to benefit from this trend, as demand for processing power and storage increases [1] Group 2: Investment Opportunities - A list of companies that are likely to gain from the heightened spending on data centers is provided, suggesting potential investment plays in this sector [1]

BEVERLY HILLS, CA / ACCESS Newswire / September 18, 2025 / Green Rain Energy Holdings (OTCID:$GREH), through its board of directors, has approved the issuance of a special stock dividend to shareholders of record. The emerging EV charging and solar energy company is poised to make great strides with this special stock dividend. ...

  Press Release   42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022)25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels. EUROAPI commits to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emiss ...

AS LHV Group has decided the company’s Financial Calendar for the 2026 financial year. In 2026 LHV Group plans to disclose information and organise the Annual General Meeting of shareholders according to the following schedule: 10.02.2026Q4 2025 and unaudited full year results12.02.2026Disclosure of Financial Plan17.02.2026January results03.03.2026Audited results for 202517.03.2026February results25.03.2026Annual General Meeting09.04.2026Ex-dividend date (ex-date)<td style="width:160.34px;;text-align: cente ...

Press Release 42% reduction in Scope 1 and 2 Greenhouse Gas emissions by 2030 (vs. 2022)25% reduction in Scope 3 GHG emissions by 2030 (vs. 2022) September 18, 2025 - EUROAPI’s near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company’s alignment with the Paris Agreement trajectory of limiting global warming to 1.5°C above pre-industrial levels. EUROAPI commits to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissi ...

Press release - regulated informationGhent, Belgium, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Substantial progress in both the U.S. and Europe in the regulatory review of Biotalys’ first candidate biofungicide EVOCA™*Patent protection for EVOCA in Brazil and China, and for a BioFun-6 lead candidate in the U.S.Strategic partnership with AgroFresh to expand into post-harvest segmentLeadership team expanded with proven industry executives Cash and cash equivalents amounted to €15.7 million as of the end of June 202 ...